Resultados de la búsqueda - Portal de Modelos de Datos Médicos (MDM-Portal)

Filtrar resultados de búsqueda
Seleccionar modelos de datos

Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

232 Resultados de la búsqueda.

Vital Signs Follow- Up (Visit 10) Ropinirole Parkinson Disease 101468/165 - Vital Signs Follow- Up (Visit 10)

- 27/9/21 - 1 formulario, 1 itemgroup, 10 items, 1 idioma

Itemgroup: Vital Signs

Study Part: Vital Signs Follow- Up (Visit 10). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Urinalysis Test Results Follow- Up (Visit 10) Ropinirole Parkinson Disease 101468/165 - Urinalysis Test Results Follow- Up (Visit 10)

- 27/9/21 - 1 formulario, 2 itemgroups, 21 items, 1 idioma

Itemgroups: URINALYSIS TEST RESULTS, Dip stick

Study Part: Urinalysis Test Results Follow- Up (Visit 10). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Laboratory Collections Follow- Up (Visit 10) Ropinirole Parkinson Disease 101468/165 - Laboratory Collections Follow- Up (Visit 10)

- 27/9/21 - 1 formulario, 1 itemgroup, 5 items, 1 idioma

Itemgroup: clinical chemistry; haematology

Study Part: Laboratory Collections Follow- Up (Visit 10). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Eligibility Parkinson's Disease NCT00656253

- 20/9/21 - 1 formulario, 2 itemgroups, 13 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

Clinical Trial on the Effectiveness of Herbal Medicinal Mixture in Parkinson Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00656253

Eligibility Parkinson's Disease NCT00892450

- 20/9/21 - 1 formulario, 2 itemgroups, 20 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00892450

Eligibility Parkinson Disease NCT00629161

- 20/9/21 - 1 formulario, 2 itemgroups, 13 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

Clinical Trial on the Effectiveness of Traditional Chinese Medicinal Mixture in Parkinson Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00629161

Eligibility Parkinson's Disease NCT01007630

- 20/9/21 - 1 formulario, 2 itemgroups, 13 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01007630

Eligibility Parkinson's Disease NCT01628965

- 20/9/21 - 1 formulario, 2 itemgroups, 17 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01628965

Eligibility Parkinson's Disease NCT00459420

- 20/9/21 - 1 formulario, 2 itemgroups, 12 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

Caffeine for Excessive Daytime Somnolence in Parkinson's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00459420

Eligibility Parkinson Disease NCT01119131

- 20/9/21 - 1 formulario, 2 itemgroups, 10 items, 1 idioma

Itemgroups: Inclusion Criteria, Exclusion Criteria

Effects of Vitamin D in Parkinson's Disease (PD); ODM derived from: https://clinicaltrials.gov/show/NCT01119131

Vital Signs Week 4 PK Visit (Visit 8) Ropinirole Parkinson Disease 101468/165 - Vital Signs Week 4 PK Visit (Visit 8)

- 20/9/21 - 1 formulario, 1 itemgroup, 11 items, 1 idioma

Itemgroup: Vital Signs

Study Part: Vital Signs Week 4 PK Visit (Visit 8). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Random Drug Screening (Urine) Week 5 PK Visit (Visit 9) Ropinirole Parkinson Disease 101468/165 - Random Drug Screening (Urine) Week 5 PK Visit (Visit 9)

- 20/9/21 - 1 formulario, 1 itemgroup, 8 items, 1 idioma

Itemgroup: DRUG SCREENING (URINE)

Study Part: Random Drug Screening (Urine) Week 5 PK Visit (Visit 9). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Utilice este formulario para comentarios, preguntas y sugerencias.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.